The effects of the proton pump inhibitor esomeprazole on the bioavailability of regorafenib in patients with a metastatic colorectal cancer (mCRC) or gastrointestinal stromal tumour (GIST).

Trial Profile

The effects of the proton pump inhibitor esomeprazole on the bioavailability of regorafenib in patients with a metastatic colorectal cancer (mCRC) or gastrointestinal stromal tumour (GIST).

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 01 Aug 2017

At a glance

  • Drugs Esomeprazole (Primary) ; Regorafenib (Primary)
  • Indications Colorectal cancer; Gastrointestinal stromal tumours
  • Focus Pharmacokinetics
  • Acronyms REGORA
  • Most Recent Events

    • 27 Jul 2017 Planned End Date changed from 1 Jun 2017 to 1 Feb 2018.
    • 27 Jul 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Dec 2017.
    • 20 Jun 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top